There is limited information present to explain temporal improvements in colon cancer survival. This nationwide study investigates the temporal changes in survival over a 35-year period (1970-2004) in Iceland and uses incidence, mortality, surgery rate, stage distribution, lymph node yield, tumor location and histological type to find explanations for these changes. Patients diagnosed with colon cancer in Iceland 1970Iceland -2004 were identified (n 5 1962). All histopathology was reassessed. Proportions, age-standardized incidence and mortality, relative, cancer-specific and overall survival and conditional survival were calculated. When comparing first and last diagnostic periods (1970-1978 and 1997-2004), 5-year relative survival improved by 12% for men and 9% for women. At the same time surgery rate increased by 12% and the proportion of stage I increased by 9%. Stage-stratified, improved 5-year relative survival was mainly observed in stages II and III and coincided with higher lymph node yields, proportional reduction of stage II cancers and proportional increase of stage III cancers, indicating stage migration between these stages. Improvement in 1-year survival was mainly observed in stages III and IV. Fiveyear survival improvement for patients living beyond 1 year was minimum to none. There were no changes in histology that coincided with neither increased incidence nor possibly influencing improved survival. Concluding, as a novel finding, 1-year mortality, which previously has been identified as an important variable in explaining international survival differences, is in this study identified as also being important in explaining temporal improvements in colon cancer survival in Iceland.
Iceland from 1970 to 2004 were included in the study. Clinicopathological data were extracted from the nationwide Icelandic Cancer Registry and all histological slides were reviewed. Intramucosal colon cancers, metachronous cancers, nonepithelial tumors and carcinoid tumours as well as cases where the origin of the primary tumor was regarded to be noncolonic (appendix, ileum, rectum, etc.) were excluded from the dataset. Depending on available clinical and pathological information, tumors of the recto-sigmoid junction were regarded either as rectal or sigmoid according to International Union Against Cancer definition. 5 Patients diagnosed and treated abroad were also excluded. The remaining 1962 colon cancer patients formed the basis of our study. When more than one primary carcinoma of the colon was present in a patient, only the tumor with the most advanced stage or stage subdivision was considered for analysis. 6 
Clinical and histopathological variables in the analysis
Date of diagnosis, patients' age at diagnosis, gender and tumor location were obtained from the records of the Icelandic Cancer Registry. Tumor location was also obtained from the original pathology report and pathology referral sheet. Tumor location was categorized into right (cecum, ascending colon, hepatic flexure, transverse colon) and left colon (splenic flexure, descending and sigmoid colon). Type of surgical treatment (surgery, i.e., colectomy or polypectomy, vs. no resection) was registered. PS and LJ reassessed all hematoxylin-eosin stained slides according to a standard protocol. Type and differentiation was reassessed according to WHO criteria. Specifically, tumors were classified as mucinous if 50% or more of the lesion was composed of extracellular mucin. Grading of differentiation was restricted to the extent of gland-formation within conventional adenocarcinomas due to the lack of criteria for other types. 7, 8 Stage was determined according to the Dukes classification with the Turnbull modification into stage A, B, C and D. 9 These stages correspond to stage I, II, III and IV of the TNMclassification. Patients with lymph node metastases were categorized as pN1 (1-3 positive nodes) and pN2 (4 or more positive lymph nodes). Those without lymph node metastases were categorized as pN0. Polypectomies and colectomies with zero lymph nodes analyzed were defaulted to pN0. Data on distant metastases were obtained both from histopathological reassessment and the pathology referral sheet. Colectomies and polypectomies were considered M0 when there were no indications of distant metastases. The unstaged category included patients with a clinical diagnosis without histological confirmation and some patients with autopsy and biopsy reports with incomplete data. Age-standardized mortality rate 
Follow-up, endpoints and survival time
Follow-up data were obtained from the Statistics Iceland. The end of the follow-up period was on December 31, 2009, giving a minimum follow-up of 5 years. The endpoints for multivariate analysis were defined as cause-specific survival, CSS (death from colon cancer), and overall survival, OS (any cause of death). Information on the cause of death was derived from death certificates and autopsy reports. Five-year and 1-year survival time for the multivariate analysis was calculated from the date of diagnosis to the date of death or censorship. For conditional version of the multivariate analysis, restricted to all patients who were still alive at one year after diagnosis, the survival time was calculated from that time point until 5 years after diagnosis. 11 For both the conventional 5-year survival and the conditional survival patients were considered censored in the survival analysis if they were still alive at 5 years after diagnosis. For 1-year survival, patients were considered censored in the survival analysis when still alive after 1 year of follow-up. For the conditional and 1-and 5-year conventional multivariate analysis patients were considered censored when they were diagnosed with second primary (metachronous) colon cancer. 12 No patients were lost to follow-up.
Statistical analysis
For statistical analysis, the dataset was divided into four diagnostic periods: 1970-1978, 1979-1987, 1988-1996 and 1997-2004 group of patients to the survival expected in the Icelandic population who are similar to the patients with regard to sex and age at diagnosis. For relative survival patients with stage IV disease and unknown stage were grouped together because of the small patient numbers and similar survival in the exploratory survival analysis within the present dataset. The Cox's proportional hazards regression model (regression method: enter; i.e., all variables were entered into the equation in one step) was used to estimate multivariate hazard ratios (HR) and 95% confidence intervals (CI) for CSS and OS. The variable of interest in the models was diagnostic periods with the last period as a reference category. We corrected multivariably for age, stage and treatment since these variables are known to be important determinants of cancer prognosis. We also corrected for gender when males and females were analyzed jointly. Because of multiple models, we only showed the HR and CI for the variable of interest, that is, diagnostic periods. This is also because age, stage and treatment were, as to be expected, significantly prognostic in all of the multivariate Cox models. Cases with zero survival time were excluded from all survival analyses (autopsy cases, n 5 51; clinical diagnosis, n 5 5). All statistical tests were two-sided. p < 0.05 was considered to indicate a significant difference in all analyses. Analyses were carried out using SPSS 20.0 (IBM Corporation) and SURV3 3.00 (Finnish Cancer Registry) software. The study was approved by the Icelandic Bioethics Committee and registered by the Icelandic Data Protection Committee.
Results
Age, gender, location, tumor type, incidence (Tables 1 and  2 ) and mortality (Supporting Information Online Table S1 and Fig. S1 )
The age distribution was stable during the whole study period. The proportion of patients undergoing colectomy rose from 74% in 1970-1978% to 84% in 1979-1987 after which it stayed at similar level. The age-standardized incidence of colon cancer almost doubled for males while it 
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seemed to level off for females. The proportion of carcinomas in the right colon increased from slightly <50% to being slightly >50% of cases (Table 1) . After age-standardization and gender stratification (Table 2) , this right-left shift persisted for males and females. After age-standardization and gender stratification, the proportions of histological types and grade remained similar for both genders over the 35-year period (Table 2) . Thus, we could not identify changes in histology that coincided with increased incidence nor possibly influencing improved survival. For the period 1970 through 2009 age-standardized mortality rates showed large fluctuations in mortality per year (as expected for a small population), but using trend analysis a slight increase in mortality for males was demonstrated while there was a reduction for females (see Supporting Information Online Table S1 and Figure S1 ).
Temporal changes in lymph node yield and stage (Tables 1 and 3)
The proportion of patients with stage I colon carcinomas increased by 9% when comparing 1970-1978 to 1997-2004 . The proportion of stage IV cancers was rather constant over time. A reduction was observed in the proportion of unstaged cancers. In contrast to the increase in the proportion of stage I cancers, there was actually a reduction in stage II carcinomas, while there was an increase in the proportion of stage III cancers. This was accompanied by a steady increase in the lymph node yield from a median of 4-10 nodes (Table 3) . It is notable that there was a steep rise in the proportion of lymph node positive cases (pN1-2) the same time as the median number of analyzed lymph nodes rose from 4 to 7. However, further increases in median of analyzed lymph nodes were accompanied by less increase in pN1-2 (Table 3) . 1 Grading was only performed for conventional adenocarcinomas. G1-2, well and moderately differentiated adenocarcinoma NOS; G3, poorly differentiated adenocarcinoma NOS; other types, mainly includes signet ring cell carcinoma and undifferentiated carcinoma.
Survival (Tables 4 and 5)
The 5-year relative colon cancer survival (Table 4) of males improved from 45% in 1970-1978% to 57% in 1997-2004, while for females it improved from 49% to 58%. For the first three diagnostic periods, the 5-year relative survival was better for female patients than for male patients, but this discrepancy was not more present in 1997-2004. In the stage-stratified analysis, improved 5-year relative survival was mainly observed in stage II and III. In stage I and IV/unstaged cases, hardly any change in 5-year relative survival was noted. However, in those stages the analysis was limited by very wide 95% CI, in stage I due to small patient numbers and in stage IV due to very low numbers of patients surviving beyond 5 years.
The 1-year relative survival also improved. Stage-stratified analysis showed that the improvement in 1-year survival was most prominent regarding patients with stage III and IV cancers.
Multivariate CSS and OS analysis, correcting for patient's age, stage and surgical treatment (Table 5) , showed an improvement in both 1-year and 5-year survival from colon cancer for both males and females when the earliest diagnostic periods were compared to the reference period (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) . When the multivariate analysis was limited to patients surviving >1 year after diagnosis (conditional survival analysis), these temporal trends largely disappeared. Patient's age, stage and surgical treatment remained prognostic in all multivariate models.
Discussion
In this study, we demonstrate a substantial improvement in 5-year relative survival of colon cancer patients in Iceland between 1970 and 2004 of 12% for men and 9% for women. In the period 1997-2004, the 5-year relative colon cancer survival was 57% for males and 58% for females, which is similar to various Northern and Central European countries for similar time period. 2 Survival improvement of European colorectal cancer patients has mostly been ascribed to earlier diagnosis and improved treatment, although the impact of each of these factors has been difficult to determine. 2 In this study, we demonstrate a relative increase in stage I cancers and surgery rate over time. Thus, earlier detection and more frequent surgical intervention likely contributed to improved survival. Importantly, we have demonstrated an improved 1-year survival, mainly in stage III and IV, while 5-year survival improvement for patients living beyond 1 year was minimum to none. This novel finding indicates that mortality reduction in the first year after diagnosis has been important for temporal improvements in colon cancer survival in Iceland. In 1 First and last diagnostic periods compared. 2 Includes stage I through IV (some stage IV cases were pN0).
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that regard, it is interesting that recent studies have demonstrated that a significant part of the international differences in colorectal cancer survival can be explained by variation in survival in the first year after colorectal cancer diagnosis.
14,15
About 30 to 40% of recurrences after operation for stage I, II and III colorectal cancer occur in the first year after surgery and 10-50% of these patients die within one year from the recurrence. [16] [17] [18] There have been few studies performed, analyzing the causes of mortality in the first year after curative surgery for colorectal cancer (stage I, II and III). The mortality has been ascribed to advanced age, prolonged impact of the assault surgery (especially in the elderly), comorbidities, emergency surgeries, postoperative complications and low socioeconomic status. [18] [19] [20] Aggressive cancer types or rapidly fatal cancer after the development of recurrence may also be associated with mortality in the first year after a curative resection. 21 Using histological type and grade of differentiation, we could, however, not identify temporal changes in histology, although temporal changes in molecular profiles cannot be excluded.
Although improved survival implies progress in cancer control many authors have pointed out that survival is a complex variable that may reflect earlier diagnosis (affected by screening or increased incidental detection), overdiagnosis, or later death (due to more effective treatment). 3, 22 Some authors propose that improved survival only represents progress when it is accompanied by reduced incidence and mortality. 22 The data from this study indicate progress in cancer control for females, shown by increased survival, stabilizing incidence and reduction of mortality. This combination is likely to indicate progress due to a combination of both increase in earlier detection without overdiagnosis and more effective treatment (and therefore later death). 22 Less progress has been achieved for men as shown by the combination of increased survival, increased incidence and increased mortality. This is likely to reflect an increase in earlier detection, perhaps together with overdiagnosis, combined with lack of improvement in treatment effectiveness. 22 These gender differences might be explained by higher prevalence of obesity among males in Iceland leading to higher incidence, 23 differences in colon cancer biology such as higher frequency of microsatellite unstable cancers among females, 24 higher frequency of comorbidities among male colon cancer patients, 25 and perhaps more effective treatment in females, for example if treatment was initiated on average earlier in the disease process than in males.
Although organized screening for colorectal cancer has not been introduced in Iceland previous studies on presenting symptoms of colon cancer in Iceland indicate that opportunistic screening or increased incidental detection has played a role in earlier detection reflected in higher frequency of stage I colon cancer. This is supported by the following; in two separate studies on colon cancer patients in Iceland, the first covering patients in National University Hospital, Reykjavik, diagnosed 1952-1971, and the second nationwide for the period 1995-2004, the percentage of patients with no presenting symptoms (patients presenting with anemia only excluded) was 1-2% in the first study but 31% in the second study. 26, 27 Increased patient and doctor awareness and improved access to diagnostic modalities, such as fecal occult blood test and mainly colonoscopy, is likely to have contributed to earlier diagnosis.
Temporal changes in diagnostic practices and work-up are also reflected in the reduction of unstaged patients and increased lymph node yield. Higher lymph node yields are likely to lead to more accurate staging, which in turn will affect stage-specific survival. The present data demonstrate a Stage IV and unstaged
CI, confidenc interval; M, male; F, female.
relative increase in stage III cancers while there was a reduction in stage II cancers, concurrently with steadily higher lymph node yields. Previous studies have shown that staging accuracy is improved by increasing lymph node yield, but only when the yield was low originally. When the number of examined lymph nodes exceeds seven nodes there is only marginal effect of increased lymph node yield on staging. 28 Data from the present study appear to support this. An increase of median number of examined lymph nodes from 4 to 7 was accompanied by a 9% increase in the proportion of pN1-2 cases. Further increases of examined lymph nodes from 7 to 10 were, however, only accompanied by a 3% rise in the proportion of pN1-2 cases. Higher lymph node yield reclassifies cancers that have just barely formed lymph node metastases to stage III. As a result, the remaining stage II cancers carry improved survival and the survival carried by the stage III cancers is also improved because of reclassification of "formerly stage II" cancers with minimal nodal burden. This type of stage migration has been referred to as the Will Rogers phenomenon. 29 In colon cancer, upstaging of patients from stage II to stage III may result in more patients being offered adjuvant We have shown slightly steeper increases in right-sided colon cancer relative to left-sided colon cancer. This increase became apparent for men only in the last diagnostic period (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) . For women the incidence rates of right-and left-sided colon cancer were quite similar and there was only a small relative increase observed for right-sided cancers. Left-right shift of colorectal cancer has also been observed in many other countries, 30 and has been speculated to be related to changes in etiology and birth cohort effects. In addition, classification bias may play some role in the left-right shift since with time the information on the precise location of tumors on the recto-sigmoid junction (i.e., rectum versus sigmoid colon) probably became more accurate.
Clinical trials have shown that patients with stage III and IV colon cancer have survival benefit from receiving systemic chemotherapy. 31, 32 It has therefore been assumed that survival improvement over time in stage III and IV is partly related to increased administration of systemic chemotherapy. The size of this contribution has been difficult to assess and some studies indicate that cytotoxic chemotherapy only makes a minor contribution to cancer survival. 33 In this study, we did not have information on chemotherapy. Still, as an indication, we know from previous studies that before 1980 chemotherapy was very rare and 1980 through 1992 only 4% of the patients that underwent colectomy received adjuvant chemotherapy. 34 For the period 1995-2004, 10% of stage II patients and close to 50 and 40% of stage III and IV patients, respectively, received systemic chemotherapy. 35 Some other limitations of our study require further discussion. We were not able to assess various factors that may influence survival, such as frequency of comorbidities, postoperative complications, emergency presentation and socioeconomic status. Another limitation of our study pertains to potential inaccuracy in the registration of distant metastases. Patient records for the presence of distant metastases were not reviewed, which may have lead to underestimation of stage IV cases, except for the most recent 10-year period (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) , as the data on distant metastases over this period are more accurate. That is because of a separate study on patients' symptoms where the patient records were reviewed and the accuracy of distant metastases was analyzed and showed 100% agreement. 27 Finally, cancer survival varies in developed countries and factors such as late presentation or cancer awareness play differing parts in this. Therefore, the external validity of the results for countries other than Iceland is unclear.
The main advantages of the current study retain to the reliability of the data. This is due to the nationwide dataset and the fact that all pathology reports and slides were reviewed. As far as we know, such detailed time trend analysis on colon cancer has not been undertaken previously.
In conclusion, we have demonstrated improved colon cancer control in Iceland during the 35-year period, mainly for women. There was a slight left-right shift observed in tumor location while the proportions of histological types remained similar. Thus, we have not identified changes in histology that coincided with increased incidence nor possibly influencing improved survival. Earlier detection (more stage I), more frequent surgical intervention and importantly reduction in 1-year mortality, mainly observed in stage III and IV, are identified as important factors relating to improved survival in Iceland.
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